MRD in AML: who, what, when, where, and how?
Jan 25, 2024 · This study provides valuable insight into the kinetics and prognostic significance of molecular MRD by NPM1 qPCR for patients with NPM1-mutated AML treated with less …
Quantitative Impact of Mutated NPM1 MRD in Patients with AML …
Nov 15, 2022 · Introduction: In NPM1-mutated (NPM1 mut) acute myeloid leukemia (AML) the detection of measurable residual disease (MRD) using quantitative PCR methods for NPM1 …
How I diagnose and treat NPM1 -mutated AML - American …
Feb 4, 2021 · NPM1 mutations are ideal targets for measurable residual disease (MRD) monitoring, since they are AML specific, frequent, very stable at relapse, and do not drive …
Minimal/Measurable Residual Disease Monitoring in NPM1 …
We summarize here the results of published studies investigating the clinical application of minimal/measurable residual disease (MRD) in patients with NPM1 -mutated AML, receiving …
MD NPM1 MRD Mutation Analysis (NGS) - MD Anderson Cancer …
NPM1 MRD assay is a genomic DNA-based NGS deep sequencing assay that targets exon 12 of the NPM1 gene. This assay can identify NPM1 mutations variants 'A,' 'B,' 'D,' and 'others' at an …
Assessment of Minimal Residual Disease in Standard-Risk AML
Feb 4, 2016 · Sensitive detection of a leukemia-specific marker (e.g., a mutation in the gene encoding nucleophosmin [NPM1]) could improve prognostication by identifying submicroscopic …
Molecular measurable residual disease monitoring and transplant ...
Nov 13, 2024 · In this review, we evaluate the prognostic role of MRD monitoring in NPM1 mutated AML and its use as a predictive biomarker to refine risk stratification and inform …
NPM1-mutation-based measurable residual disease assessment …
This study aimed to investigate the optimal timing and cutoff value to ascertain the value of NPM1 mutation in MRD assessment. NPM1-mutated MRD was quantified by real-time polymerase …
Measurable Residual Mutated NPM1 before Allogeneic Transplant …
Measurable residual disease (MRD) testing before allogeneic hematopoietic cell transplant (alloHCT) for persistence of mutated NPM1 or FLT3 -ITD in AML patients in complete …
Quantifying NPM1 MRD in AML patients prior to allogeneic stem …
Here we systematically analyzed different NPM1 MRD thresholds to identify NPM1 ‐mutated AML patients at high risk of relapse following HSCT. We retrospectively analyzed 81 NPM1 …